<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00880841</url>
  </required_header>
  <id_info>
    <org_study_id>20-A93-AU</org_study_id>
    <nct_id>NCT00880841</nct_id>
  </id_info>
  <brief_title>A Single-Dose Study of an Investigational Capsule Formulation of 2 mg/0.5 mg Buprenorphine/Naloxone</brief_title>
  <official_title>A Single-Dose, 1-Period, 1-Treatment Pilot Study of an Investigational Capsule Formulation of 2 mg/.05 mg Buprenorphine/Naloxone Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NanoSHIFT LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NanoSHIFT LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single-dose pilot study of an investigational capsule formulation of 2 mg/.05 mg&#xD;
      Buprenorphine/Naloxone.&#xD;
&#xD;
      NIDA Contract No. HHSN271200577414C&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>pharmacokinetic profile of an investigational formulation of buprenorphine HCl/naloxone HCl 2mg/0.5mg oral capsules</measure>
    <time_frame>pk blood draws over a 72 hour period</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>no treatment</arm_group_label>
    <description>phase 1a study for healthy normals</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine / Naloxone</intervention_name>
    <description>oral formulation of buprenorphine / naloxone</description>
    <arm_group_label>no treatment</arm_group_label>
    <other_name>NanoBUP</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        healthy normals between the ages of 18 and 55 (inclusive)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject must be a male or non-pregnant, non-breastfeeding female.&#xD;
&#xD;
          -  Subject must be between 18 and 55 years of age (inclusive).&#xD;
&#xD;
          -  Subject's Body Mass Index (BMI) must be between 18 and 30 kg/m2 (inclusive), and&#xD;
             subject must weigh a minimum of 50 kg (110 lbs).&#xD;
&#xD;
          -  Female subjects - not surgically sterile for at least 6 months or at least 2 years&#xD;
             postmenopausal - must agree to utilize one of the following forms of contraception, if&#xD;
             sexually active with a male partner, from screening through completion of the study.&#xD;
             Approved forms of contraception are abstinence, hormonal (oral, implant, transdermal,&#xD;
             vaginal, or injection) in use at least 3 consecutive months prior to the first dose of&#xD;
             study medication, double barrier (condom with spermicide; diaphragm with spermicide),&#xD;
             intrauterine device (IUD), or vasectomized partner (6 months minimum since vasectomy).&#xD;
&#xD;
          -  Subject must voluntarily consent to participate in this study and provide their&#xD;
             written informed consent prior to start of any study-specific procedures.&#xD;
&#xD;
          -  Subject is willing and able to remain in the study unit for the entire duration of the&#xD;
             confinement period and return for any outpatient visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of clinically significant cardiovascular, pulmonary, hepatic,&#xD;
             renal, hematologic, gastrointestinal, endocrine, immunologic, metabolic, dermatologic,&#xD;
             neurologic, oncologic, or psychiatric disease or any other condition that, in the&#xD;
             opinion of the Investigator, would jeopardize the safety of the subject or the&#xD;
             validity of the study results.&#xD;
&#xD;
          -  Has a clinically significant abnormal finding on the physical exam, medical history,&#xD;
             ECG, or clinical laboratory results at screening.&#xD;
&#xD;
          -  History or presence of allergic or adverse response to buprenorphine, naloxone,&#xD;
             naltrexone, opioids, or any comparable or similar products.&#xD;
&#xD;
          -  Has been on a significantly abnormal diet during the 4 weeks preceding the first dose&#xD;
             of study medication.&#xD;
&#xD;
          -  Has donated blood or plasma within 30 days prior to the first dose of study&#xD;
             medication.&#xD;
&#xD;
          -  Has participated in another clinical trial within 30 days prior to the first dose of&#xD;
             study medication.&#xD;
&#xD;
          -  Has used any over-the-counter (OTC) medication, including nutritional supplements,&#xD;
             within 7 days prior to the first dose of study medication.&#xD;
&#xD;
          -  Has used any prescription medication, except hormonal contraceptive or hormonal&#xD;
             replacement therapy, within 14 days prior to the first dose of study medication.&#xD;
&#xD;
          -  Has been treated with any known enzyme altering drugs, such as barbiturates,&#xD;
             phenothiazines, cimetidine, carbamazepine, etc., within 30 days prior to the first&#xD;
             dose of study medication.&#xD;
&#xD;
          -  Has smoked or used tobacco products within 60 days prior to the first dose of study&#xD;
             medication.&#xD;
&#xD;
          -  Has history of substance abuse or dependence (including alcohol, opioids, or&#xD;
             intravenous drug abuse)&#xD;
&#xD;
          -  Is a female with a positive pregnancy test result.&#xD;
&#xD;
          -  Has a positive urine screen for drugs of abuse (amphetamines, barbiturates,&#xD;
             benzodiazepines, cannabinoids, cocaine, opiates).&#xD;
&#xD;
          -  Has a positive urine alcohol test at screening or a positive ethanol breath test at&#xD;
             check-in for the study period or has consumed alcohol within 48 hours prior to&#xD;
             screening or check-in for the study period.&#xD;
&#xD;
          -  Has had a positive test for, or has been treated for hepatitis B, hepatitis C, or HIV.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Leibowitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CEDRA Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CEDRA Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>April 13, 2009</study_first_submitted>
  <study_first_submitted_qc>April 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2009</study_first_posted>
  <last_update_submitted>June 21, 2017</last_update_submitted>
  <last_update_submitted_qc>June 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy normals, phase 1</keyword>
  <keyword>phase 1a study for healthy normals</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

